LTFS
CRVS icon

Ladenburg Thalmann Financial Services’s Corvus Pharmaceuticals CRVS Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-15,350
Closed -$220K – 4854
2016
Q4 		$220K Buy
15,350
+5,900
+62% +$89.7K ﹤0.01% 1754
2016
Q3 		$155K Buy
+9,450
New +$136K ﹤0.01% 1928

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ladenburg Thalmann Financial Services's CRVS Position: Q1 2017 in Review

Ladenburg Thalmann Financial Services sold out of Corvus Pharmaceuticals (CRVS) in Q1 2017, closing a stake of 15,350 shares — an estimated $220K sold.

Ladenburg Thalmann Financial Services first reported a position in CRVS in Q3 2016 and held it in 2 quarters. The position peaked at $220K in Q4 2016. 52 funds tracked by Wall St. Rank hold CRVS as of Q1 2017.

  • Ladenburg Thalmann Financial Services reported no remaining Corvus Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Ladenburg Thalmann Financial Services sold 15,350 Corvus Pharmaceuticals shares in Q1 2017, an estimated $220K.
  • Ladenburg Thalmann Financial Services first reported a position in Corvus Pharmaceuticals in Q3 2016 and held it in 2 quarters.
  • Ladenburg Thalmann Financial Services's Corvus Pharmaceuticals position peaked at $220K in Q4 2016.
  • 52 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2017.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q1 2017, filed 15 May 2017.